Strides Pharma Gets USFDA Nod for Generic Pregabalin

Jan 25, 2024 20:20

Strides Pharma Science subsidiary receives USFDA approval for generic Pregabalin capsules, a medication for nerve pain. The product is bio-equivalent to Lyrica capsules and has a market size of USD 248 million in the US.

Photograph: Yves Herman/Reuters

New Delhi, Jan 25 (PTI) Strides Pharma Science on Thursday said its subsidiary has received approval from the US health regulator for a generic medication for nerve pain.

Singapore-based Strides Pharma Global Pte has received approval for Pregabalin capsules from the US Food & Drug Administration (USFDA), the drug maker said in a regulatory filing.

The company's product is bio-equivalent and therapeutically equivalent to the reference listed drug -- Lyrica capsules -- used in the treatment of fibromyalgia.

As per IQVIA data, Pregabalin capsules have a market size of USD 248 million in the US market.

Shares of Strides Pharma Science on Thursday ended 2.27 per cent up at Rs 685.75 apiece on the BSE.

MORE NEWS

Coal Mining: Panel Urges Faster Green Clearances

Parliamentary panel urges faster environmental & forest clearances for coal mining...

DCM Shriram & Bayer Crop Science Collaboration

DCM Shriram and Bayer Crop Science partner to explore agricultural opportunities in...

Silver Price Soars to Rs 1.92 Lakh/kg on Global...

Silver prices surge Rs 11,500 to Rs 1.92 lakh/kg in Delhi amid strong global cues. Gold...

Urea Fixed Costs to Rise for Manufacturers

Govt plans to raise fixed costs for urea makers by year-end. Decision expected soon,...

Bullion Rates Today: Gold & Silver Prices

Check today''s closing bullion rates in Bengaluru. Gold (22K & 24K) prices per gram and...

Bank of India Raises Rs 2,500 Cr via Tier II Bonds

Bank of India (BoI) raised Rs 2,500 crore through Basel III-compliant Tier II bonds at...

Cipla Launches Obesity & Diabetes Drug Yurpeak

Cipla launches Yurpeak (tirzepatide), a weekly injectable for obesity and type-2...

Sebi Eases KYC for NRIs, Removes Physical Presence

Sebi relaxes re-KYC for NRIs, removing physical presence requirement for digital...

OPTCL & NABARD Pact: Power Boost in Odisha

OPTCL and NABARD sign MoU for power infrastructure development in Odisha. NABARD...

CG Power Turnaround: Srinivasan's Book

N Srinivasan's book chronicles CG Power's revival from bankruptcy to a USD 10 billion...

Strides Pharma Gets USFDA Nod for Generic Pregabalin

You May Like To Read

MORE NEWS